Evidence-led peptide reference
IGF-1 LR3 research guide
Also known as: Long R3 IGF-1
Updated 10 October 2026 · Editorial standards
A modified IGF-1 analogue used to investigate growth-factor signalling in experimental systems.
Identity and context
What is IGF-1 LR3?
IGF-1 LR3, or Long R3 IGF-1, is a laboratory-modified analogue of insulin-like growth factor 1. It contains an arginine substitution at position three and an added N-terminal extension. These changes distinguish it from naturally circulating human IGF-1.
The analogue was designed to bind less strongly to several IGF-binding proteins, increasing free experimental activity and extending its action in some systems. That makes it useful as a research reagent but also means natural IGF-1 evidence cannot simply be copied across.
Mechanism under investigation
How is IGF-1 LR3 studied?
IGF-1 receptor activation influences PI3K-AKT and MAPK-related signalling involved in cell survival, protein synthesis, glucose handling, proliferation and differentiation. These are fundamental pathways rather than bodybuilding-specific mechanisms.
Reduced binding-protein interaction can change tissue exposure and potency. More persistent growth signalling is not automatically beneficial; it raises safety questions involving hypoglycaemia, abnormal tissue growth and the biology of existing tumours.
Research map
Main areas of interest
Cell growth and differentiation
Researchers use LR3 in cell culture to stimulate IGF-1 receptor pathways and study tissue development.
Protein and muscle biology
Experimental models examine protein synthesis and muscle-cell signalling, but this does not establish safe performance enhancement.
Metabolic signalling
IGF pathways interact with insulin and glucose regulation, creating both research interest and hypoglycaemia concerns.
Strength of evidence
What does the evidence actually show?
Evidence is separated by level because a cell experiment, an animal model, a human trial and a regulatory decision answer different questions.
Critical reading
Limitations and unanswered questions
- Natural IGF-1 physiology and modified LR3 exposure are not equivalent.
- Growth signalling can affect many tissues, including unwanted or abnormal cell populations.
- Potential hypoglycaemia and interaction with insulin pathways are material safety concerns.
- Analytical identity is especially important because closely related growth factors and analogues cannot be distinguished by name alone.
Analytical context
What a certificate of analysis can—and cannot—tell you
A certificate of analysis is a report about the particular submitted sample and tests named on that report. It can help document identity, measured amount or purity when suitable methods were used. It does not prove that every batch is identical, that a material is sterile or endotoxin-free, that it is clinically effective, or that it is approved for human use.
No product-specific COA is currently linked to this guide. Absence of a displayed report should not be interpreted as analytical verification.
Learn how to read a peptide COA →Questions answered
IGF-1 LR3 FAQs
What does LR3 mean?
It refers to the longer analogue with an arginine substitution at position three and an N-terminal extension.
Is IGF-1 LR3 natural human IGF-1?
No. It is a deliberately modified analogue with different binding-protein interactions and experimental behaviour.
Is it a proven muscle-building medicine?
No. Experimental pathway activity does not establish a safe or approved bodybuilding treatment.
Why do binding proteins matter?
IGF-binding proteins regulate distribution and availability. Reduced binding can increase free activity and change exposure.
Primary and authoritative reading
Sources and further reading
Sources are provided so readers can inspect the underlying literature and current official information. Inclusion does not mean every claim in a paper has been independently confirmed.
- Long R3 IGF-1 study in pigs ↗Original animal study reporting growth and endocrine outcomes; findings do not establish a human benefit.
- Long R3 IGF-1 study in guinea pigs ↗Original animal experiment on organ growth and circulating IGF measures.
- IGF-1 biology review ↗Open-access review of IGF-1 physiology and signalling context.
Source and wording review: 7 October 2026. Prepared with AI assistance; no independent clinical review is claimed. Read the editorial policy or suggest a correction.